Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

   Terminated · Phase 2, Phase 3 · Acute-graft-versus-host Disease

   NCT03805789 · Csl Behring · 12 U.S. investigators

   $1.4Mresearch payments

2. Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

   Active, not recruiting · Phase 2 · Chronic Lymphocytic Leukemia (CLL)

   NCT03824483 · Beone Medicines USA, Inc. · 1 U.S. investigator

   $1.4Mresearch payments

3. A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

   Recruiting · Phase 2 · Monoclonal Gammopathy of Undetermined Significance (MGUS)

   NCT06140524 · Regeneron Pharmaceuticals, Inc. · 8 U.S. investigators

   $1.4Mresearch payments

4. Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

   Active, not recruiting · Phase 3 · Follicular Lymphoma (FL)

   NCT05409066 · AbbVie Inc. · 35 U.S. investigators

   $1.4Mresearch payments

5. Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

   Completed · Phase 4 · Prostate Cancer

   NCT06604442 · Blue Earth Diagnostics · 9 U.S. investigators

   $1.4Mresearch payments

6. (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

   Active, not recruiting · Phase 2 · Indolent Systemic Mastocytosis

   NCT03731260 · Blueprint Medicines Corporation · 16 U.S. investigators

   $1.4Mresearch payments

7. A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

   Active, not recruiting · Phase 3 · Atopic Dermatitis

   NCT06461897 · AbbVie Inc. · 27 U.S. investigators

   $1.4Mresearch payments

8. Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

   Active, not recruiting · Phase 1 · SCLC,Extensive Stage

   NCT05595460 · E.r. Squibb & Sons, L.l.c. · 16 U.S. investigators

   $1.4Mresearch payments

9. A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

   Active, not recruiting · Phase 2, Phase 3 · Non-small Cell Lung Cancer

   NCT05800015 · Regeneron Pharmaceuticals, Inc. · 27 U.S. investigators

   $1.4Mresearch payments

10. Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

    Active, not recruiting · Phase 3 · Melanoma

    NCT05352672 · Regeneron Pharmaceuticals, Inc. · 8 U.S. investigators

    $1.4Mresearch payments

11. A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

    Active, not recruiting · Phase 1 · Relapsed/Refractory Multiple Myeloma

    NCT05259839 · AbbVie Inc. · 14 U.S. investigators

    $1.4Mresearch payments

12. A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

    Terminated · Phase 2 · Merkel Cell Carcinoma

    NCT04916002 · Regeneron Pharmaceuticals, Inc. · 15 U.S. investigators

    $1.4Mresearch payments

13. Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

    Completed · Phase 3 · Chronic Obstructive Pulmonary Disease

    NCT04751487 · Sanofi US Services Inc. · 59 U.S. investigators

    $1.4Mresearch payments

14. First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

    Active, not recruiting · Phase 1 · Endometrial Cancer

    NCT05527184 · AbbVie Inc. · 33 U.S. investigators

    $1.4Mresearch payments

15. A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

    Completed · Phase 2 · Rheumatoid Arthritis

    NCT06073093 · Sanofi US Services Inc. · 19 U.S. investigators

    $1.4Mresearch payments

16. Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

    Active, not recruiting · Transfusion-dependent Beta-Thalassemia

    NCT02633943 · Genetix Biotherapeutics Inc · 7 U.S. investigators

    $1.4Mresearch payments

17. Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects

    Enrolling by invitation · Phase 3 · Bipolar I Disorder

    NCT04987229 · Alkermes, Inc. · 23 U.S. investigators

    $1.4Mresearch payments

18. A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

    Completed · Phase 1 · Healthy

    NCT06503679 · Eli Lilly and Company · 1 U.S. investigator

    $1.3Mresearch payments

19. Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

    Active, not recruiting · Phase 3 · Advanced Colorectal Cancer

    NCT04793958 · Mirati Therapeutics, Inc. · 51 U.S. investigators

    $1.3Mresearch payments

20. Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)

    Recruiting · Phase 1 · PD - Parkinson's Disease

    NCT06482268 · Sumitomo Pharma Co., Ltd. · 1 U.S. investigator

    $1.3Mresearch payments

21. A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

    Completed · Phase 2 · Diabetic Peripheral Neuropathy

    NCT06074562 · Eli Lilly and Company · 34 U.S. investigators

    $1.3Mresearch payments

22. A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

    Enrolling by invitation · Phase 3 · Duchenne Muscular Dystrophy

    NCT05967351 · Sarepta Therapeutics, Inc. · 24 U.S. investigators

    $1.3Mresearch payments

23. A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

    Active, not recruiting · Phase 2, Phase 3 · Advanced Non-Small Cell Lung Cancer

    NCT05785767 · Regeneron Pharmaceuticals, Inc. · 22 U.S. investigators

    $1.3Mresearch payments

24. Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

    Completed · Phase 3 · Schizophrenia

    NCT04578756 · AbbVie Inc. · 34 U.S. investigators

    $1.3Mresearch payments

25. A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

    Active, not recruiting · Phase 2 · Ulcerative Colitis

    NCT06257875 · AbbVie Inc. · 49 U.S. investigators

    $1.3Mresearch payments

26. A Study of BG-C477 in Participants With Advanced Solid Tumors

    Recruiting · Phase 1 · Advanced Solid Tumors

    NCT06596473 · Beone Medicines USA, Inc. · 4 U.S. investigators

    $1.3Mresearch payments

27. A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

    Terminated · Phase 2 · Human Immuno-deficiency Virus (HIV) Disease

    NCT06032546 · AbbVie Inc. · 38 U.S. investigators

    $1.3Mresearch payments

28. Cryoablation for Monomorphic Ventricular Tachycardia

    Active, not recruiting · Not applicable · Sustained VT

    NCT05675865 · Adagio Medical, Inc. · 10 U.S. investigators

    $1.3Mresearch payments

29. A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

    Active, not recruiting · Phase 1, Phase 2 · Neovascular Age-related Macular Degeneration

    NCT06660667 · Sanofi US Services Inc. · 20 U.S. investigators

    $1.3Mresearch payments

30. Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

    Active, not recruiting · Phase 2 · Unresectable Metastatic Colorectal Cancer

    NCT06107413 · AbbVie Inc. · 18 U.S. investigators

    $1.3Mresearch payments

31. Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

    Terminated · Phase 1 · Non-Small Cell Lung Cancer

    NCT04892017 · Deciphera Pharmaceuticals Inc. · 12 U.S. investigators

    $1.3Mresearch payments

32. A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

    Completed · Phase 2 · Plaque Psoriasis

    NCT06602219 · Eli Lilly and Company · 13 U.S. investigators

    $1.3Mresearch payments

33. Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

    Terminated · Phase 3 · RSV Immunization

    NCT06397768 · Sanofi Pasteur Inc. · 46 U.S. investigators

    $1.3Mresearch payments

34. Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

    Terminated · Phase 1 · Multiple Myeloma

    NCT03486067 · Celgene Corporation · 6 U.S. investigators

    $1.3Mresearch payments

35. RESTORE: An RCT to Evaluate the Efficacy of the Revi System

    Active, not recruiting · Not applicable · Urinary Urge Incontinence

    NCT06217328 · Bluewind Medical · 32 U.S. investigators

    $1.3Mresearch payments

36. SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

    Active, not recruiting · Phase 3 · Plasma Cell Myeloma Recurrent

    NCT05405166 · Sanofi US Services Inc. · 17 U.S. investigators

    $1.3Mresearch payments

37. Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

    Completed · Phase 2 · Neuroendocrine Tumors

    NCT05997056 · Aadi Bioscience, Inc. · 3 U.S. investigators

    $1.3Mresearch payments

38. A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

    Recruiting · Phase 1, Phase 2 · Propionic Acidemia

    NCT05130437 · ModernaTX, Inc. · 6 U.S. investigators

    $1.3Mresearch payments

39. Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

    Recruiting · Phase 1, Phase 2 · Metastatic Breast Cancer

    NCT06590857 · E.r. Squibb & Sons, L.l.c. · 20 U.S. investigators

    $1.2Mresearch payments

40. A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

    Active, not recruiting · Phase 3 · Myelodysplastic Syndromes

    NCT06045689 · E.r. Squibb & Sons, L.l.c. · 20 U.S. investigators

    $1.2Mresearch payments

41. A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

    Active, not recruiting · Phase 3 · Obesity

    NCT06075667 · Eli Lilly and Company · 10 U.S. investigators

    $1.2Mresearch payments

42. Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

    Terminated · Phase 1 · Solid Tumor

    NCT05737706 · E.r. Squibb & Sons, L.l.c. · 14 U.S. investigators

    $1.2Mresearch payments

43. Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Active, not recruiting · Phase 1 · Multiple Myeloma

    NCT06223516 · AbbVie Inc. · 7 U.S. investigators

    $1.2Mresearch payments

44. Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

    Recruiting · Phase 1, Phase 2 · Propionic Acidemia

    NCT04159103 · ModernaTX, Inc. · 13 U.S. investigators

    $1.2Mresearch payments

45. REal-World Analyses of Stroke - Thrombus Occlusion REtrieval

    Completed · Acute Ischemic Stroke

    NCT04451525 · Microvention, Inc. · 32 U.S. investigators

    $1.2Mresearch payments

46. A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

    Active, not recruiting · Phase 2 · Eosinophilic Gastritis (EoG)

    NCT05831176 · Regeneron Pharmaceuticals, Inc. · 38 U.S. investigators

    $1.2Mresearch payments

47. Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

    Active, not recruiting · Phase 1 · Advanced Solid Tumors Cancer

    NCT03821935 · AbbVie Inc. · 21 U.S. investigators

    $1.2Mresearch payments

48. A Study of LY3437943 in Healthy Participants With a High Body Mass Index

    Completed · Phase 1 · Healthy

    NCT05959096 · Eli Lilly and Company · 1 U.S. investigator

    $1.2Mresearch payments

49. A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

    Active, not recruiting · Phase 3 · Episodic Migraine

    NCT03432286 · Eli Lilly and Company · 28 U.S. investigators

    $1.2Mresearch payments

50. A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

    Recruiting · Phase 1 · Advanced Solid Tumor

    NCT05765851 · Daiichi Sankyo Inc. · 4 U.S. investigators

    $1.2Mresearch payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.